Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 3/20 | 0.80 |
| ▸ | YAP1 | P46937 | 1/20 | 0.80 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | TNNI3K | Q59H18 | 6/20 | 0.47 |
| ▸ | BRAF | P15056 | 3/20 | 0.46 |
| ▸ | IDH2 | P48735 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | CDK7 | P50613 | 1/20 | 0.42 |
| ▸ | CCNH | P51946 | 1/20 | 0.42 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20767258 | 0.91 | TEAD1 (0.85) | TEAD1YAP1MAPTTNNI3KBRAF | |
| SCHEMBL29438871 | 0.89 | TEAD1 (1.00) | TEAD1YAP1MAPTTNNI3KEGFR | |
| SCHEMBL20779435 | 0.89 | TEAD1 (1.00) | TEAD1YAP1MAPTTNNI3KEGFR | |
| SCHEMBL20767446 | 0.88 | TEAD1 (0.62) | TEAD1YAP1MAPTTNNI3KBRAF | |
| SCHEMBL29901779 | 0.88 | TEAD1 (0.62) | TEAD1YAP1MAPTTNNI3KBRAF | |
| SCHEMBL29901824 | 0.86 | TEAD1 (0.60) | TEAD1YAP1MAPTTNNI3KBRAF | |
| SCHEMBL20766734 | 0.86 | TEAD1 (0.60) | TEAD1YAP1MAPTTNNI3KBRAF | |
| SCHEMBL29901832 | 0.86 | TEAD1 (0.67) | TEAD1YAP1MAPTTNNI3KBRAF | |
| SCHEMBL20766878 | 0.86 | TEAD1 (0.67) | TEAD1YAP1MAPTTNNI3KBRAF | |
| SCHEMBL22718028 | 0.85 | TEAD1 (0.59) | TEAD1YAP1MAPTTNNI3KBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024092116-A1 | COMBINATION OF TEAD INHIBITORS AND EGFR INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-11760728-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760728-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| CN-111542315-B | Benzosulfonyl compounds | 维瓦斯治疗公司 | 2023-05-12 | — | — | CN | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| EP-3691623-B1 | BENZOSULFONYL COMPOUNDS | VIVACE THERAPEUTICS INC (US) | 2022-10-05 | — | — | EP | disclosed |
| WO-2022187518-A1 | SUBSTITUTED 4-PIPERIDINYL-IMIDAZO[4,5-B]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | Ikena Oncology, Inc. (US) | 2022-09-09 | — | — | WO | disclosed |
| WO-2022120355-A1 | TEAD DEGRADERS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-06-09 | — | — | WO | disclosed |
| US-11274082-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-03-15 | — | — | US | disclosed |
| US-11192865-B2 | Benzosulfonyl compounds | VIVACE THERAPEUTICS, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-20200407327-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2020-12-31 | — | — | US | disclosed |
| WO-2020243423-A1 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2020-12-03 | — | — | WO | disclosed |
| WO-2020243415-A2 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2020-12-03 | — | — | WO | disclosed |
| US-20200354325-A1 | BENZOSULFONYL COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2020-11-12 | — | — | US | disclosed |
| US-20200354325-A1 | BENZOSULFONYL COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2020-11-12 | — | — | US | disclosed |
| CN-111542315-A | Benzosulfonyl compounds | 维瓦斯治疗公司 | 2020-08-14 | — | — | CN | disclosed |
| EP-3691623-A1 | BENZOSULFONYL COMPOUNDS | Vivace Therapeutics, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| WO-2019040380-A1 | BENZOSULFONYL COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019040380-A1 | BENZOSULFONYL COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | TEAD1 4/4885YAP1 111/4885MAPT 507/4885 |
| US-11274082-B2 | Tead inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | TEAD1 4/4885YAP1 111/4885MAPT 507/4885 |
| US-11192865-B2 | Benzosulfonyl compounds | YAP1, TEAD2, TEAD1 | TEAD1 3/4885YAP1 1/4885MAPT 2341/4885 |
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | TEAD1 1/4885YAP1 9/4885MAPT 516/4885 |
| US-11760728-B2 | Tead inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | TEAD1 4/4885YAP1 111/4885MAPT 507/4885 |
| US-20200407327-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | TEAD1 4/4885YAP1 111/4885MAPT 507/4885 |
| US-20200354325-A1 | BENZOSULFONYL COMPOUNDS | YAP1, TEAD2, TEAD1 | TEAD1 3/4885YAP1 1/4885MAPT 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.